Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses.

The journal of prevention of Alzheimer's disease·2026
Same author

Generating synthetic tau-PET scans in Alzheimer's disease from MRI, blood biomarkers and demographics with deep learning.

medRxiv : the preprint server for health sciences·2026
Same author

Interchangeability of CSF and PET to identify Alzheimer's disease pathology.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Neuropathological correlates of age and sex differences in 18F-flortaucipir PET.

Brain : a journal of neurology·2026
Same author

Late-life body mass index and amyloid interaction on cognitive decline in unimpaired older adults.

The journal of prevention of Alzheimer's disease·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Vikas Kotari1, Karen Chilcott Holdridge2, Roy Yaari2

  • 1Eli Lilly and Company, Indianapolis, IN, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary
This summary is machine-generated.

This study analyzed tau positron emission tomography (PET) scans in preclinical Alzheimer's disease (AD) participants. Results show tau deposition patterns similar to other preclinical AD cohorts, even in those with mild cognitive impairment.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neurology
  • Radiology
  • Gerontology

Background:

  • Preclinical Alzheimer's disease (AD) is characterized by amyloid buildup but preserved cognition.
  • Most participants in the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial lacked significant tau accumulation.
  • The TRAILBLAZER-ALZ 3 trial investigates donanemab efficacy in preclinical AD.

Purpose of the Study:

  • To characterize and compare baseline tau positron emission tomography (PET) scans from the TRAILBLAZER-ALZ 3, A4, and TRAILBLAZER-ALZ 2 studies.
  • To analyze tau distribution in preclinical AD populations using flortaucipir F 18 (FTP) PET scans.

Main Methods:

  • Utilized data from 310 participants in the TRAILBLAZER-ALZ 3 trial, categorized by Clinical Dementia Rating-Global Score (CDR-GS 0 and CDR-GS 0.5).
  • Employed flortaucipir F 18 (FTP) tau PET imaging and an established pipeline for analyzing global tau burden and regional patterns.
  • Defined tau positivity using standardized uptake value ratio (SUVR) cut points (>1.11 for positive scan, >1.46 for high tau level).

Main Results:

  • 13.3% of CDR0 and 25.5% of CDR0.5 participants showed positive tau PET scans (SUVR > 1.11).
  • Medial and lateral temporal lobes exhibited the highest regional baseline SUVRs in both subgroups.
  • Average SUVRs indicated a sequential deposition pattern: medial temporal > lateral temporal > parietal > frontal lobes.

Conclusions:

  • Baseline tau PET patterns in TRAILBLAZER-ALZ 3 are consistent with other preclinical AD populations, including the CDR0.5 subgroup.
  • Observed tau deposition patterns support a sequential progression from medial temporal to frontal lobes.
  • Further regional analyses are planned to provide deeper insights into tau distribution.